PharmaEssentia Corporation (TPE:6446)
Taiwan · Delayed Price · Currency is TWD | Market Cap | 169.63B |
| Revenue (ttm) | 11.34B |
| Net Income (ttm) | 3.90B |
| Shares Out | 333.27M |
| EPS (ttm) | 11.67 |
| PE Ratio | 43.63 |
| Forward PE | 25.00 |
| Dividend | 1.10 (0.22%) |
| Ex-Dividend Date | n/a |
| Volume | 919,464 |
| Average Volume | 1,400,134 |
| Open | 501.00 |
| Previous Close | 498.50 |
| Day's Range | 501.00 - 509.00 |
| 52-Week Range | 440.00 - 796.00 |
| Beta | -0.08 |
| RSI | 43.81 |
| Earnings Date | Aug 12, 2025 |
About Regulus Therapeutics
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutro... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)
Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. ("PharmaEssentia") and AOP Orphan Pharmaceuti...